University Medical Center Groningen
Anthracyclines(University Medical Center Groningen)은 Toxicity Due to Chemotherapy 표적 치료제로, Toxicity Due to Chemotherapy; Cardiovascular Morbidity 영역에서 개발·상용화 중입니다. 작용기전: targeting IL-4/IL-13 signaling. 전임상 단계입니다. OS: 65.04. 차별점: novel chemosensitizing agents to overcome multidrug resistance (MDR) in hematological malignancies (HMs).
Toxicity Due to Chemotherapy
Toxicity Due to Chemotherapy; Cardiovascular Morbidity
Recruiting
bispecific antibodies, and antibody-drug conjugates, which are reshapi
release
novel chemosensitizing agents to overcome multidrug resistance (MDR) in hematological malignancies (HMs)
targeting IL-4/IL-13 signaling
cytokine release syndrome monitoring, caregiver burden, financial toxicity, and adherence challenges
DNA damage response (DDR) (RAD51i B02; HDACi entinostat (EST))
biomarkers, quality of life, and exploring the role of traditional cardiovascular risk factors in CTRCD onset
downregulation of multidrug resistance protein 1 (MDR1; P-glycoprotein) and multidrug resistance-associated protein 1 (MRP1) in specif
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
University Medical Center Groningen
Anthracyclines(University Medical Center Groningen)은 Toxicity Due to Chemotherapy 표적 치료제로, Toxicity Due to Chemotherapy; Cardiovascular Morbidity 영역에서 개발·상용화 중입니다. 작용기전: targeting IL-4/IL-13 signaling. 전임상 단계입니다. OS: 65.04. 차별점: novel chemosensitizing agents to overcome multidrug resistance (MDR) in hematological malignancies (HMs).
Toxicity Due to Chemotherapy
Toxicity Due to Chemotherapy; Cardiovascular Morbidity
Recruiting
bispecific antibodies, and antibody-drug conjugates, which are reshapi
release
novel chemosensitizing agents to overcome multidrug resistance (MDR) in hematological malignancies (HMs)
targeting IL-4/IL-13 signaling
cytokine release syndrome monitoring, caregiver burden, financial toxicity, and adherence challenges
DNA damage response (DDR) (RAD51i B02; HDACi entinostat (EST))
biomarkers, quality of life, and exploring the role of traditional cardiovascular risk factors in CTRCD onset
downregulation of multidrug resistance protein 1 (MDR1; P-glycoprotein) and multidrug resistance-associated protein 1 (MRP1) in specif
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.